Which asthma biologic do docs prefer? It's not that simple: analyst

From Roche and Novartis’ aging Xolair to Sanofi and Regeneron’s newcomer Dupixent, along with meds from respiratory nemeses AstraZeneca and GlaxoSmithKline, several biologics are vying for a bigger share of the asthma market. Which one of them do doctors prefer? Surprisingly, there is no clear winner, according to one analyst.